Mucolytic Therapy in Cystic Fibrosis

Carlstedt I. Davies J. Mucins in the respiratory tract. XIIIth International Cystic Fibrosis Congress, Stockholm, Sweden 2000; 31(suppl): 40–1

Girod S. Zahm J.M. Plotkowski C. Beck G. Puchelle E. Role of the physiochemical properties of mucus in the protection of the respiratory epithelium. Eur Respir J 1992; 5: 47–87

Jayaraman S. Song Y. Verkman AS . Non-invasive in vivo fluorescence measurement for airway surface liquid properties—depth, salt concentration, pH and viscosity. Pediatr Pulmonol 2000; S20: 122–3

Davis P. Drumm M. Konstan MW . Cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1229–56

Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Review Respir Dis 1968; 98: 597–8

Ranasinha C. Assoufi B. Shak S. Efficacy and safety of short-term administration of acrolised recombinant human DNase 1 in adults with stable stage cystic fibrosis. Lancet 1993; 342: 199–202

Ramsey B.W. Astley S.J. Aitken M.L. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 145–51

Fuchs H.J. Borowitz D.S. Christiansen D.H. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Enal J Med 1994; 331: 637–42

Thomson AH . DNase and other mucolytics. In: Dodge J.A. Brock D.J.H. Widdicombe J.H. , eds. Cystic Fibrosis Current Topics. Chichester: John Wiley & Sons, 1966: 289–310

Robert G. Stevens A. Colin-Jones D. Dornase alpha for cystic fibrosis BMJ 1995; 311: 813

Innes JA . DNase in cystic fibrosis: the challenge of assessing response and maximising benefit. Thorax 1998; 53: 1003–4

Zach MS . The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises more problems. Thorax 1996; 51: 750–5

Perks B. Warner J.O. Shute JK . Increase in free IL-8 concentration and the chemotactic response of neutrophils to DNase treated cystic fibrosis sputum. [Abstract] Pediatr Pulmonol 1997; suppl 14

Vogelmeier C. Doring G. Neutrophil proteinases and rhDNase therapy in cystic fibrosis. Eur Respir J 1996; 9: 2193–5

Ramsey B.W. Dorkin HL . Consensus conference: practical applications of Pulmozyme. Pediatr Pulmonol 1994; 17: 404–8

Bush A. Hodson M.E. Geddes D.M. Dornase alfa for cystic fibrosis. Patients should not be denied a safe, effective treatment [Letter]. BMJ 1995; 310: 1533

Davies J. Trindade M.T. Wallis C. Rosenthal M. Crawford O. Bush A. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997; 23: 243–8

Davies J. Trindale M. Wallis C. Rosenthal M. Bush A. The clinical use of rhDNAsc. Pediatr Pulmonol 1997; 16(Suppl): 273–5

Thomson AH . Human recombinant DNase in cystic fibrosis J R Soc Med 1995; 88: 24–9

Wagener J.S. Rock M.J. McCubbin M.M. Hamilton S.D. Johnson C.A. Ahrens RC . Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. J Pediatr 1998; 133: 48–91

Kearney C.E. Wallis CE . Deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2000; CD001127

Suri R. Metcalfe C. Lees B. A randomised comparative trial of hypertonic saline, alternate day and daily rHDNase in children with cystic fibrosis. Thorax 2000; 55(suppl 3): A75

Konstan M.W. Wohl M.E. McKenzie S. Sy J.P. Quan J.M. Tiddens HA . A randomized, placebo-controlled trial of two years’ treatment with dornase alfa (Pulmozyme) in cystic fibrosis patients aged 6–10 years with early lung disease [abstract]. Pediatr Pulmonol 2000; 20(suppl): 299–500

Wojnarowski C. Eichler J. Frischer T. Storm K. Renner S. Gotz M. RhDNase therapy in patients with CF: is it possible to predict lung function improvement? Pediatr Pulmonol 1995; 12(suppl): 237

Cobos N. Danes I. Gartner S. Gonzalez M. Linan S. Arnau JM . DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. Eur J Pediatr 2000; 159: 170–81

Milla CE . Long term effects of aerolised rhDNase on pulmonary disease progression in patients with cystic fibrosis. Thorax 1998; 53: 1014–17

Dasgupta B. Tomkiewicz R.P. Brown N.E. King M. Combined effects of hypertonic saline and rhDNase on cystic fibrosis sputum in vitro. Pediatr Pulmonol 1995; 20: 236

Robinson M. Hemming A.L. Regnis J.A. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 2000; 52: 900–3

Robinson M. Regnis J.A. Bailey D.L. King M. Bautovich G.J. Bye PTP . Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996; 153: 1503–9

Wark P.A.B. McDonald V. Nebulised hypertonic saline for cystic fibrosis (Cochrane review). In: The Cochrane library. Oxford: Update Software, 2000

Suri R. Wallis C. Bush A. Tolerability of nebulised hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol 2000; 20(suppl): 306

Folkesson H.G. Kheradmand F. Matthay MA . The effect of salt water on alveolar epithelial barrier function. Am J Respir Crit Care 1994; 150: 1555–63

Riedler J. Reade T. Button B. Robertson CF . Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. J Paediatr Child Health 1996; 32: 43–50

Eng P.A. Morton J. Douglass J.A. Riedler J. Wilson J. Robertson CF . Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996; 21: 77–83

Duijvestijn Y.C. Brand PL . Systematic review of N-acetylcysteine in cystic fibrosis. Acta Paediatr 1999; 88: 38–41.

Dreisin R.B. Mostow SR . Sulfhydryl-medialed depression of ciliary activity: an adverse effect of acetylcysteine. J Lab Clin Med 1979; 93: 67–8

Dano G. Bronchospasm caused by acetylcysteine in children with bronchial asthma. Acta Alleraol 1971; 26: 181–90

Howatt W.F. DeMuth GR . A double-blind study of the use of acetylcysteine in patients with cystic fibrosis. Uni Mich Med Centre J 1966; 32: 82–5

Gotz M. Kraemer R. Kerrebijn K.F. Popow C. Oral acetylcysteine in cystic fibrosis. A co-operative study. Eur J Respir Dis 1980; 111(suppl): 122–6

Mitchell E.A. Elliott RB . Controlled trial of oral N-acetylcysteine in cystic fibrosis. Aust Paediatr J 1982; 18: 40–2

Ratjen F. Wonne R. Posselt H.G. Stover B. Hofmann D. Bender SW . A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr 1985; 144: 37–8

Stafanger G. Garne S. Howitz P. Morkassel E. Koch C. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J 1988; 1: 161–7

Dasgupta B. King M. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase. Pediatr Pulmonol 1996; 22: 161–6

Malfroot A. Dab I. Baran D. App E.M. Coffiner M. Nagy AM . Randomised multicententric double blind study of tolerability and efficacy of a DPI Nacystelyn versus placebo in cystic fibrosis patients treated by rhDNase for at least 3 months [Abstract]. XIIIth International Cystic Fibrosis Congress, Stockholm, Sweden 2000; 146

Hirsch S.R. Zastrow J.E. Kory RC . Sputum liquefying agents: a comparative in vitro evaluation. J Lab Clin Med 1969; 74: 346–53

Weller P.H. Ingram D. Preece M.A. Matthew DJ . Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax 1980; 35: 42–6

Heaf D. Webb G.J. Matthew DJ . In vitro assessment of combined antibiotic and mucolytic treatment for Pseudomonas aeruginosa infection in cystic fibrosis. Arch Dis Child 1983; 58: 824–36

Vasconcellos C.A. Allen P.G. Wohl M.E. Drazen J.M. Janmey P.A. Stossel TP . Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263: 969–71

Davoodian K. Ritchings B.W. Ramphal R. Buchana J.A. Bubb MR . Gelsolin activates DNase 1 in vitro and cystic fibrosis sputum. Biochemistry 1997; 36: 9637–41

Daviskas E. Andersen D.H. Brannon J.D. Chan H.K. Eberl S. Bautovich G. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J 1997; 10: 2449–54

Robinson M. Daviskas E. Eberl S. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999; 14: 678–85

Knowles M.R. Church N. Wattner W.E. A pilot study of aerolised amiloride for the treatment of lung disease in cystic fibrosis. N Engl Med 1990; 322: 1189–94

App E. King M. Helfesrieder R. Kohler D. Matthys H. Acute and long term amiloride inhalation in cystic fibrosis lung disease. Am Rev Respir Dis 1990; 141: 605–12

Middleton P.G. Geddes D.M. Alton EW . Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects. Thorax 1993; 48: 812–6

Ballmann M. Hardt Hvd . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [Abstract]. Pediatr Pulmonol 1998; S17: 343

Suri R. Wallis C. Bush A. In vivo use of hypertonic saline in CF [Abstract]. Pediatr Pulmonol 2000; S20: 125–6

Guyatt G. Sackett D. Taylor D.W. Chong J. Roberts R. Pugsley S. Determining optimal therapy —randomized trials in individual patients. N Eng J Med 1986; 314: 889–92

Week M.B. Retsch-Bogan G.Z. Scott CS . Efficacy of DNase in individual children using the n-of-1 study design. Pediatr Pulmonol 1999; 19(Suppl): 285

Bollert F.G.E. Paton J.Y. Marshall T.G. Calvert J. Greening A.P. Innes JA . Recombinant DNase in cystic fibrosis, a protocol for targeted introduction through n-of-1 trials. Eur Respir J 1999; 13: 107–13

Larson E.B. Ellsworth A.J. Oas J. Randomized clinical trials in single patients during a 2-year period. JAMA 1993; 270: 2708–12